Status:
COMPLETED
Bevacizumab Against Recurrent Retinal Detachment
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Retinal Detachment
Proliferative Vitreoretinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Eyes with rhegmatogenous retinal detachment
Exclusion
- Presence of PVR
- Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
- Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
- Secondary retinal detachment repair
- Use of silicone oil as tamponade agent
- Patients less than 18 years of age
- Pregnancy
- Known allergy or contraindication to intravitreal bevacizumab
Key Trial Info
Start Date :
January 21 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2019
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT02192970
Start Date
January 21 2015
End Date
November 11 2019
Last Update
March 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53705